Increased Mortality Associated With Low Use of Clopidogrel in Patients With Heart Failure and Acute Myocardial Infarction Not Undergoing Percutaneous Coronary Intervention

S. Harris, D. Tepper, Randy J. Ip
{"title":"Increased Mortality Associated With Low Use of Clopidogrel in Patients With Heart Failure and Acute Myocardial Infarction Not Undergoing Percutaneous Coronary Intervention","authors":"S. Harris, D. Tepper, Randy J. Ip","doi":"10.1111/J.1751-7133.2010.00173.X","DOIUrl":null,"url":null,"abstract":"Abstract. Objectives. We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart failure (HF) not receiving percutaneous coronary intervention (PCI). \n \n \n \nBackground. Use of clopidogrel after AMI is low in patients with HF, despite the fact that clopidogrel is associated with absolute mortality reduction in AMI patients. \n \n \n \nMethods. All patients hospitalized with first-time AMI (2000 through 2005) and not undergoing PCI within 30 days from discharge were identified in national registers. Patients with HF treated with clopidogrel were matched by propensity score with patients not treated with clopidogrel. Similarly, 2 groups without HF were identified. Risks of all-cause death were obtained by the Kaplan–Meier method and Cox regression analyses. \n \n \n \nResults. We identified 56,944 patients with first-time AMI. In the matched cohort with HF (n=5050) and a mean follow-up of 1.50 years (SD=1.2), 709 (28.1%) and 812 (32.2%) deaths occurred in patients receiving and not receiving clopidogrel treatment, respectively (P=.002). The corresponding numbers for patients without HF (n=6092), with a mean follow-up of 2.05 years (SD=1.3), were 285 (9.4%) and 294 (9.7%), respectively (P=.83). Patients with HF receiving clopidogrel demonstrated reduced mortality (hazard ratio, 0.86; 95% confidence interval, 0.78–0.95) compared with patients with HF not receiving clopidogrel. No difference was observed among patients without HF (hazard ratio, 0.98; 95% confidence interval, 0.83–1.16). \n \n \n \nConclusions. Clopidogrel was associated with reduced mortality in patients with HF who do not undergo PCI after their first-time AMI, whereas this association was not apparent in patients without HF. Further studies of the benefit of clopidogrel in patients with HF and AMI are warranted.—Bonde L, Sorensen R, Fosbol EL, et al. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. J Am Coll Cardiol. 2010;55:1300–1307.","PeriodicalId":10536,"journal":{"name":"Congestive heart failure","volume":"26 1","pages":"239-239"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Congestive heart failure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/J.1751-7133.2010.00173.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract. Objectives. We studied the association of clopidogrel with mortality in acute myocardial infarction (AMI) patients with heart failure (HF) not receiving percutaneous coronary intervention (PCI). Background. Use of clopidogrel after AMI is low in patients with HF, despite the fact that clopidogrel is associated with absolute mortality reduction in AMI patients. Methods. All patients hospitalized with first-time AMI (2000 through 2005) and not undergoing PCI within 30 days from discharge were identified in national registers. Patients with HF treated with clopidogrel were matched by propensity score with patients not treated with clopidogrel. Similarly, 2 groups without HF were identified. Risks of all-cause death were obtained by the Kaplan–Meier method and Cox regression analyses. Results. We identified 56,944 patients with first-time AMI. In the matched cohort with HF (n=5050) and a mean follow-up of 1.50 years (SD=1.2), 709 (28.1%) and 812 (32.2%) deaths occurred in patients receiving and not receiving clopidogrel treatment, respectively (P=.002). The corresponding numbers for patients without HF (n=6092), with a mean follow-up of 2.05 years (SD=1.3), were 285 (9.4%) and 294 (9.7%), respectively (P=.83). Patients with HF receiving clopidogrel demonstrated reduced mortality (hazard ratio, 0.86; 95% confidence interval, 0.78–0.95) compared with patients with HF not receiving clopidogrel. No difference was observed among patients without HF (hazard ratio, 0.98; 95% confidence interval, 0.83–1.16). Conclusions. Clopidogrel was associated with reduced mortality in patients with HF who do not undergo PCI after their first-time AMI, whereas this association was not apparent in patients without HF. Further studies of the benefit of clopidogrel in patients with HF and AMI are warranted.—Bonde L, Sorensen R, Fosbol EL, et al. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. J Am Coll Cardiol. 2010;55:1300–1307.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
未经皮冠状动脉介入治疗的心力衰竭和急性心肌梗死患者低剂量使用氯吡格雷与死亡率增加相关
抽象。目标。我们研究了氯吡格雷与未接受经皮冠状动脉介入治疗(PCI)的急性心肌梗死(AMI)合并心力衰竭(HF)患者死亡率的关系。背景。心衰患者AMI后氯吡格雷的使用率较低,尽管事实上氯吡格雷与AMI患者的绝对死亡率降低有关。方法。所有因首次急性心肌梗死住院(2000 - 2005)且出院后30天内未接受PCI治疗的患者均在国家登记册中确定。接受氯吡格雷治疗的HF患者与未接受氯吡格雷治疗的患者进行倾向评分匹配。同样,2组无HF。通过Kaplan-Meier法和Cox回归分析获得全因死亡风险。结果。我们确定了56,944例首次AMI患者。在HF匹配队列中(n=5050),平均随访1.50年(SD=1.2),接受氯吡格雷治疗和未接受氯吡格雷治疗的患者分别有709例(28.1%)和812例(32.2%)死亡(P= 0.002)。在平均随访2.05年(SD=1.3)的情况下,无HF患者(n=6092)的相应人数分别为285人(9.4%)和294人(9.7%)(P= 0.83)。接受氯吡格雷治疗的心衰患者死亡率降低(风险比,0.86;95%可信区间,0.78-0.95)与未接受氯吡格雷治疗的HF患者相比。无HF患者间无差异(风险比,0.98;95%置信区间为0.83-1.16)。结论。氯吡格雷与首次AMI后未行PCI治疗的心衰患者死亡率降低相关,而这种相关性在非心衰患者中不明显。氯吡格雷对心衰和AMI患者的益处的进一步研究是有必要的。-Bonde L, Sorensen R, Fosbol EL,等。在心衰和急性心肌梗死患者中,未接受经皮冠状动脉介入治疗的低剂量氯吡格雷与死亡率增加相关:一项全国性研究中华心血管病杂志。2010;22(5):391 - 391。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Comparison of Hospital Mortality With Intra‐Aortic Balloon Counterpulsation Insertion Before vs After Primary Percutaneous Coronary Intervention for Cardiogenic Shock Complicating Acute Myocardial Infarction Increased Mortality Associated With Low Use of Clopidogrel in Patients With Heart Failure and Acute Myocardial Infarction Not Undergoing Percutaneous Coronary Intervention Heart Failure: Current Clinical Understanding Pathophysiology of volume overload in acute heart failure syndromes Dynamic Cardiovascular Risk Assessment in Elderly People
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1